---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-068614"
form_type: "8-K"
ticker: "TPST"
cik: "0001544227"
company_name: "Tempest Therapeutics, Inc."
filed_at: "2026-02-25T23:59:59+00:00"
generated_at: "2026-05-16T00:16:46.031782+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Tempest reports 100% CR rate in REDEEM-1 trial; plans U.S. registrational study in 2026

## Summary
- 100% complete response (CR) rate among all six efficacy-evaluable patients in REDEEM-1 trial of TPST-2003 in rrMM.
- Favorable safety profile: no Grade ≥3 CRS or ICANS across dose levels in REDEEM-1.
- Prior 24-patient IIT showed 89.5% CR rate and median progression-free survival of 23.1 months.
- Tempest plans to submit U.S. IND and initiate registrational study of TPST-2003 in 2026, subject to clearance.
- Company exploring TPST-2003 in LBCL; expects initial data from TPST-3003 and TPST-4003 programs later in 2026.

## SEC filing metadata
- accession: 0001193125-26-068614
- form_type: 8-K
- ticker: TPST
- cik: 0001544227
- company_name: Tempest Therapeutics, Inc.
- filed_at: 2026-02-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1544227/000119312526068614/0001193125-26-068614-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1544227/000119312526068614/d22967d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-068614
- JSON: https://secwatch.observer/filing/0001193125-26-068614.json
- Plain text: https://secwatch.observer/filing/0001193125-26-068614.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.